Teva Pharmaceutical (TEVA) Reports In-Line Q2 EPS
Teva Pharmaceutical (NYSE: TEVA) reported Q2 EPS of $1.20, in-line with the analyst estimate of $1.20. Revenue for the quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)